International Assets Investment Management LLC Takes $950,000 Position in Hologic, Inc. (NASDAQ:HOLX)

International Assets Investment Management LLC bought a new position in shares of Hologic, Inc. (NASDAQ:HOLX) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 13,290 shares of the medical equipment provider’s stock, valued at approximately $950,000.

A number of other large investors have also recently bought and sold shares of the company. McGlone Suttner Wealth Management Inc. acquired a new stake in Hologic during the 4th quarter valued at approximately $27,000. Venturi Wealth Management LLC purchased a new stake in Hologic in the third quarter valued at $29,000. NBC Securities Inc. acquired a new stake in Hologic during the 3rd quarter worth about $33,000. Deseret Mutual Benefit Administrators raised its stake in shares of Hologic by 42.2% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 155 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV lifted its holdings in shares of Hologic by 69.4% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 227 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insider Activity at Hologic

In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the transaction, the director now directly owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction on Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the transaction, the director now owns 1,572 shares in the company, valued at approximately $119,802.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Karleen Marie Oberton sold 14,940 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the completion of the sale, the chief financial officer now directly owns 103,916 shares of the company’s stock, valued at approximately $7,793,700. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,846 shares of company stock valued at $2,473,443. Corporate insiders own 1.75% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and lifted their price target for the company from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Evercore ISI increased their price target on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Hologic in a report on Wednesday, April 10th. StockNews.com downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. Finally, Raymond James raised their target price on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. Six research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $87.00.

Hologic Price Performance

Shares of Hologic stock opened at $76.22 on Tuesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. The business has a 50 day simple moving average of $75.80 and a two-hundred day simple moving average of $72.64. The stock has a market capitalization of $17.89 billion, a P/E ratio of 36.12, a PEG ratio of 2.55 and a beta of 1.00. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $87.88.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. During the same quarter last year, the firm posted $1.07 EPS. The firm’s revenue for the quarter was down 5.7% on a year-over-year basis. As a group, analysts predict that Hologic, Inc. will post 4.01 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.